142 related articles for article (PubMed ID: 9095325)
1. Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le(a), sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine.
Ravindranath MH; Bauer PM; Amiri AA; Miri SM; Kelley MC; Jones RC; Morton DL
Anticancer Drugs; 1997 Mar; 8(3):217-24. PubMed ID: 9095325
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA.
Ravindranath MH; Bauer PM; Cornillez-Ty C; Garcia J; Morton DL
J Immunol Methods; 1996 Oct; 197(1-2):51-67. PubMed ID: 8890894
[TBL] [Abstract][Full Text] [Related]
3. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
4. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.
Habal N; Gupta RK; Bilchik AJ; Yee R; Leopoldo Z; Ye W; Elashoff RM; Morton DL
Ann Surg Oncol; 2001 Jun; 8(5):389-401. PubMed ID: 11407512
[TBL] [Abstract][Full Text] [Related]
5. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
6. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
7. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
Hsueh EC; Gupta RK; Qi K; Morton DL
J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
[TBL] [Abstract][Full Text] [Related]
8. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.
O'Boyle KP; Zamore R; Adluri S; Cohen A; Kemeny N; Welt S; Lloyd KO; Oettgen HF; Old LJ; Livingston PO
Cancer Res; 1992 Oct; 52(20):5663-7. PubMed ID: 1394190
[TBL] [Abstract][Full Text] [Related]
9. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
[TBL] [Abstract][Full Text] [Related]
10. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.
Ravindranath MH; Kelley MC; Jones RC; Amiri AA; Bauer PM; Morton DL
Int J Cancer; 1998 Jan; 75(1):117-24. PubMed ID: 9426699
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.
Hakomori S
Adv Exp Med Biol; 2001; 491():369-402. PubMed ID: 14533809
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
13. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
DiFronzo LA; Gupta RK; Essner R; Foshag LJ; O'Day SJ; Wanek LA; Stern SL; Morton DL
J Clin Oncol; 2002 Aug; 20(15):3242-8. PubMed ID: 12149297
[TBL] [Abstract][Full Text] [Related]
14. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
[TBL] [Abstract][Full Text] [Related]
15. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
[TBL] [Abstract][Full Text] [Related]
16. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
17. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
18. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
[TBL] [Abstract][Full Text] [Related]
19. Impact of minimal tumor burden on antibody response to vaccination.
Kim SK; Wu X; Ragupathi G; Gathuru J; Koide F; Cheung NK; Panageas K; Livingston PO
Cancer Immunol Immunother; 2011 May; 60(5):621-7. PubMed ID: 21267719
[TBL] [Abstract][Full Text] [Related]
20. Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn.
O'Boyle KP; Coatsworth S; Anthony G; Ramirez M; Greenwald E; Kaleya R; Steinberg JJ; Dutcher JP; Wiernik PH
Cancer Immun; 2006 Mar; 6():5. PubMed ID: 16524255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
